Telomere syndrome
MONDO:0100137Accelerated aging syndromes often caused by inheritable gene mutations resulting in decreased telomere lengths.
Also known as: STS, short telomere syndrome
80 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThis study tests a new drug called elafibranor in people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants either did not get enough help from or could not take the standard medicine. The goal is to see if elafi…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for liver disease: drug shows promise in reducing damage
Disease control OngoingThis study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug im…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to normalize liver enzyme in bile duct disease
Disease control OngoingThis study tests whether elafibranor, a daily pill, can normalize alkaline phosphatase (ALP) levels in adults with primary biliary cholangitis (PBC) who did not respond well to or cannot take standard treatment. About 69 participants will receive either elafibranor or a placebo f…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for PBC patients: experimental drug K-808 enters Mid-Stage trial
Disease control OngoingThis study tests two doses of K-808 (Pemafibrate) in 46 adults with primary biliary cholangitis (PBC) who haven't responded well to standard treatments. The main goal is to see if the drug lowers alkaline phosphatase (ALP) levels, a key marker of liver damage, after 12 weeks. Par…
Phase: PHASE2 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Hope for liver disease: new drug trial targets PBC symptoms
Disease control OngoingThis study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and helps control the disease. About 102 adults who completed a previous PBC study will take the drug and be mon…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for PBC patients: Long-Term safety trial of seladelpar underway
Disease control OngoingThis study is testing the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who have taken seladelpar before will receive either 5 mg or 10 mg daily for several years. Researchers will monitor …
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy shows promise in early sarcoma trial
Disease control OngoingThis study tests a new drug (ADI-PEG 20) combined with chemotherapy and radiation before surgery for soft tissue sarcoma. The goal is to find the safest dose and see how well it shrinks tumors. Only 6 patients with intermediate or high-grade sarcoma of the trunk or limbs are taki…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental infusion aims to fix bone marrow failure in rare telomere disease
Disease control OngoingThis early-stage trial tests a single infusion of EXG34217 in 12 people aged 12 and older who have bone marrow failure due to telomere biology disorders. The main goal is to check safety and tolerability, while also looking at changes in telomere length and blood cell counts. Bec…
Phase: PHASE1 • Sponsor: Elixirgen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a cholesterol drug help fight a rare liver disease?
Disease control OngoingThis study tests whether adding fenofibrate (a drug used for high cholesterol) to standard treatment with ursodeoxycholic acid can improve liver health in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 184 adults with PBC will receive either…
Phase: PHASE2, PHASE3 • Sponsor: Han Ying • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for Hard-to-Treat liver disease: steroid combo trial launches
Disease control ENROLLING_BY_INVITATIONThis study looks at whether adding prednisone to standard UDCA treatment helps people with primary biliary cholangitis (PBC) who also have moderate to severe interface hepatitis, a type of liver inflammation. About 244 adults will be randomly assigned to receive either UDCA alone…
Phase: PHASE2, PHASE3 • Sponsor: Han Ying • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Simple blood test could spot hidden liver disease in women
Diagnosis OngoingThis study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for relieving severe itch in liver disease
Symptom relief OngoingThis study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can a smartwatch help manage a rare liver disease? stanford study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study at Stanford University is testing whether wearable devices like smartwatches can help measure fatigue, sleep, and daily activity in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare data from the wearables with patient que…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study tracks blood sugar in liver disease patients on common drug
Knowledge-focused OngoingThis study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Gene study aims to unlock secrets of progressive lung disease
Knowledge-focused OngoingThis study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how in…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
1,200-Patient study aims to predict liver failure risks
Knowledge-focused OngoingThis observational study follows 1,222 adults with liver cirrhosis to understand why some develop serious complications like fluid buildup or bleeding. Participants have check-ups every six months, including questionnaires, physical exams, and imaging. The goal is to build better…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused TerminatedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC